Stay updated with breaking news from Basal Insulin. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
A Utah mother is fighting for her teen daughter’s access to diabetes medicine after it was discontinued. Alison Smart, plus other parents and medical experts, discussed the risks and options.
1. In this randomized controlled trial, insulin icodec demonstrated superior HbA1c reduction as compared to once-daily basal insulin analogs in insulin-naïve type two diabetes (T2D). 2. Insulin icodec showed improved treatment satisfaction and compliance as compared to once-daily basal insulin analogs in insulin naïve T2D. Evidence Rating Level: 1 (Excellent) Study Rundown: Two prior phase three randomized
1. In this randomized controlled trial, insulin icodec demonstrated superior HbA1c reduction as compared to once-daily basal insulin analogs in insulin-naïve type two diabetes (T2D). 2. Insulin icodec showed improved treatment satisfaction and compliance as compared to once-daily basal insulin analogs in insulin naïve T2D. Evidence Rating Level: 1 (Excellent) Study Rundown: Two prior phase
Basal Insulin (Long-Acting Insulin) Market | Biocon, Eli Lilly
New Dexcom product with 15-day wear, a cash-pay option and a tailored software experience for people who don't use insulin is expected to launch in the U.S. in 2024 Access and availability of Dexcom CGM is expanding